Eva Maria Schleicher, Simon Johannes Gairing, Darko Castven, Charlotte Sophie Hock, Henrike Dobbermann, Sophia Heinrich, Myriam Meineck, Leonard Kaps, Peter Robert Galle, Julia Weinmann-Menke, Marc Nguyen-Tat, Jens Uwe Marquardt, Christian Labenz
Hepatorenal syndrome (HRS) is associated with a dismal prognosis in patients with cirrhosis, and therapeutic options are limited. Biomarkers to identify patients with poor response to therapy are urgently needed. This study aimed to evaluate the predictive value of serum levels of Uromodulin (sUMOD) in patients with cirrhosis and HRS treated with terlipressin and albumin (T/A). In total, 156 patients (81 patients with HRS treated with T/A, 42 patients with cirrhosis without kidney injury and 33 patients with cirrhosis with prerenal acute kidney injury (AKI)) were included...
March 19, 2024: American Journal of Physiology. Gastrointestinal and Liver Physiology